While mouse models such as the KrasLSL-G12D/+; Pdx1-Cre [3] and KrasLSL-G12D/+; Trp53LSL-R172H/+; and Pdx1-Cre [4] were particularly useful for studying several aspects of pancreatic cancer biology, thus far therapies evaluated primarily in these preclinical models were not translated into improved clinical outcomes for patients. This evidence concerns the gene PDX1 and pancreatic neoplasm.